ECSP15015022A - Moduladores de quinolinilo unidos a metileno de ror-gamma-t - Google Patents

Moduladores de quinolinilo unidos a metileno de ror-gamma-t

Info

Publication number
ECSP15015022A
ECSP15015022A ECIEPI201515022A ECPI201515022A ECSP15015022A EC SP15015022 A ECSP15015022 A EC SP15015022A EC IEPI201515022 A ECIEPI201515022 A EC IEPI201515022A EC PI201515022 A ECPI201515022 A EC PI201515022A EC SP15015022 A ECSP15015022 A EC SP15015022A
Authority
EC
Ecuador
Prior art keywords
ror
gamma
methylene
quinolinyl modulators
linked quinolinyl
Prior art date
Application number
ECIEPI201515022A
Other languages
English (en)
Inventor
Kevin D Kreutter
Maud Urbanski
Umar Maharoof
David A Kummer
Steven Goldberg
Kristi A Leonard
Kent Barbay
Hariharan Venkatesan
James P Edwards
Aihua Wang
Joan Pierce
Ronald L Wolin
Rachel Nishimura
Anne Fourie
Xiaohua Xue
Craig R Woods
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP15015022A publication Critical patent/ECSP15015022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente invención comprende los compuestos de la Fórmula (I) (ver anexo) en donde: R1, R2, R3, R4, R5, R6, R7, R8 y R9 son tal como se definieron en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde ese síndrome, trastorno o enfermedad es artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de RORyt en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de por lo menos un compuesto de la reivindicación 1.
ECIEPI201515022A 2012-10-16 2015-04-15 Moduladores de quinolinilo unidos a metileno de ror-gamma-t ECSP15015022A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261714419P 2012-10-16 2012-10-16
US201261725528P 2012-11-13 2012-11-13
US201361782257P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
ECSP15015022A true ECSP15015022A (es) 2016-01-29

Family

ID=49546611

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201515022A ECSP15015022A (es) 2012-10-16 2015-04-15 Moduladores de quinolinilo unidos a metileno de ror-gamma-t

Country Status (38)

Country Link
US (1) US9290476B2 (es)
EP (1) EP2909192B1 (es)
JP (1) JP6466335B2 (es)
KR (1) KR20150070347A (es)
CN (1) CN105209453B (es)
AR (1) AR093017A1 (es)
AU (1) AU2013331496B2 (es)
BR (1) BR112015008308A2 (es)
CA (1) CA2888210C (es)
CL (1) CL2015000945A1 (es)
CR (1) CR20150193A (es)
CY (1) CY1119234T1 (es)
DK (1) DK2909192T3 (es)
EA (1) EA026415B1 (es)
EC (1) ECSP15015022A (es)
ES (1) ES2632269T3 (es)
GT (1) GT201500093A (es)
HK (1) HK1213248A1 (es)
HR (1) HRP20171082T1 (es)
HU (1) HUE035335T2 (es)
IL (1) IL237866B (es)
LT (1) LT2909192T (es)
ME (1) ME02794B (es)
MX (1) MX358508B (es)
MY (1) MY189505A (es)
NI (1) NI201500053A (es)
NZ (1) NZ706775A (es)
PE (1) PE20150778A1 (es)
PH (1) PH12015500817A1 (es)
PL (1) PL2909192T3 (es)
PT (1) PT2909192T (es)
RS (1) RS56283B1 (es)
SG (1) SG11201502369XA (es)
SI (1) SI2909192T1 (es)
TW (1) TWI606045B (es)
UY (1) UY35084A (es)
WO (1) WO2014062658A1 (es)
ZA (1) ZA201503418B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860099A1 (en) * 2012-02-13 2013-08-22 Johannes Aebi Imidazolylketone derivatives asd aldosterone synthase inhibitors
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US9096596B2 (en) 2013-03-14 2015-08-04 Janssen Pharmaceutica Nv P2X7 modulators
TW201522307A (zh) 2013-03-14 2015-06-16 百靈佳殷格翰國際股份有限公司 經取代２－氮雜－雙環［２．２．１］庚烷－３－羧酸（苄基－氰基－甲基）－醯胺組織蛋白酶ｃ抑制劑
US9663469B2 (en) 2013-09-09 2017-05-30 Bristol-Myers Squibb Company RORγ modulators
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
JP6320523B2 (ja) * 2013-10-15 2018-05-09 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγＴの第二級アルコールキノリニルモジュレータ
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) * 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) * 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
KR20160068957A (ko) * 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. Ror-gamma-t의 메틸렌 결합 퀴놀리닐 조절제
SG11201609722UA (en) * 2014-05-28 2016-12-29 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6578349B2 (ja) 2014-08-11 2019-09-18 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
SI3191487T1 (sl) 2014-09-12 2019-12-31 Boehringer Ingelheim International Gmbh Spirociklični inhibitorji katepsina C
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
EP4038070A1 (en) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
CN114502535B (zh) * 2019-10-31 2024-04-12 江苏恒瑞医药股份有限公司 一种RORγ调节剂的酸加成盐
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
JP2023523300A (ja) 2020-04-30 2023-06-02 イドーシア ファーマシューティカルズ リミテッド Ｃｃｒ６受容体調節剤としてのアゼチジン－３－イルメタノール誘導体
CN112939974B (zh) * 2021-03-11 2023-10-20 中山大学 一种氮杂苯并薁衍生物的制备方法
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023072924A1 (en) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
TW202325271A (zh) 2021-10-28 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772U (es) 1971-08-02 1973-03-31
ATE27451T1 (de) 1981-03-24 1987-06-15 Ciba Geigy Ag Acyl-chinolinonderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische praeparate und ihre verwendung.
US4656283A (en) 1982-05-25 1987-04-07 American Cyanamid Company Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid
US4910327A (en) 1982-05-25 1990-03-20 American Cyanamid Company Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid: dialkyl 3-(substituted)phenylaminobut-2-ene-dioates and methods for the preparation thereof
US4710507A (en) 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
FR2634483B2 (fr) 1987-12-29 1994-03-04 Esteve Labor Dr Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
ES2136782T3 (es) 1994-10-27 1999-12-01 Asahi Glass Co Ltd Procedimiento para producir compuestos de acido quinolin-2-il-benzoico.
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
CA2231105C (en) 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
CA2254769A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2290992C (en) * 1997-06-02 2008-02-12 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
RU2220960C2 (ru) 1997-12-22 2004-01-10 Фармация Энд Апджон Компани 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе
FR2776388B1 (fr) 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
TR200003879T2 (tr) 1998-07-06 2007-01-22 Janssen Pharmaceutica N.V. İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
CA2337800C (en) * 1998-07-06 2007-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
JP2000169451A (ja) 1998-09-30 2000-06-20 Kyorin Pharmaceut Co Ltd ６，７―ジ置換キノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
ATE240327T1 (de) 1998-12-23 2003-05-15 Janssen Pharmaceutica Nv 1,2-annelierte chinolinderivate
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
EA200100766A1 (ru) 1999-02-11 2002-02-28 Пфайзер Продактс Инк. Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
ES2262626T3 (es) 2000-02-04 2006-12-01 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para tratar cancer de mama.
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
AU2001256166A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP1261374A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525237A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
CA2397475A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2001064198A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001252147A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
AU2001240658A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
US20030022918A1 (en) 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
CA2397425A1 (en) 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with taxane compounds
EP1261348A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
EP1261356A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
US6844357B2 (en) 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
ATE276262T1 (de) 2000-07-12 2004-10-15 Upjohn Co Oxazinochinolone für die behandlung viraler infektionen
US6624159B2 (en) 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
ATE321038T1 (de) 2000-09-25 2006-04-15 Janssen Pharmaceutica Nv Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
BR0114253A (pt) 2000-10-02 2003-07-01 Janssen Pharmaceutica Nv Antagonistas de receptor de glutamato metabotrópico
WO2002043733A1 (en) 2000-11-28 2002-06-06 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
WO2002051835A1 (en) 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
EP1365763B1 (en) 2001-02-15 2008-11-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2002070487A1 (en) 2001-03-01 2002-09-12 Pharmacia & Upjohn Company Substituted quinolinecarboxamides as antiviral agents
EP1390033A1 (en) 2001-04-25 2004-02-25 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
WO2003000705A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
BR0215067A (pt) 2001-12-20 2004-11-09 Upjohn Co Piridoquinoxalinas antivirais
JP2005530681A (ja) 2001-12-20 2005-10-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピリドキノキサリン抗ウイルス剤
NZ535438A (en) 2002-03-29 2006-08-31 Janssen Pharmaceutica Nv Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
EP2045242A1 (en) 2002-08-13 2009-04-08 Shionogi&Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
AU2003262947A1 (en) 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
GB0222516D0 (en) 2002-09-27 2002-11-06 Karobio Ab Novel compounds
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005054201A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CN1890224B (zh) 2003-12-05 2011-06-08 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的6-取代的2-喹啉酮和2-喹喔啉酮
UA91007C2 (ru) 2003-12-10 2010-06-25 Янссен Фармацевтика Н.В. Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
TW200529845A (en) 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
DK1711181T3 (da) 2004-01-23 2010-02-01 Janssen Pharmaceutica Nv Quinolin-derivater og anvendelse af disse som mycobakterielle inhibitorer
CA2554049C (en) 2004-01-29 2012-12-18 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
JP2005225250A (ja) 2004-02-10 2005-08-25 Murakami Corp 車載用監視装置
DE602005026391D1 (de) 2004-06-30 2011-03-31 Janssen Pharmaceutica Nv Chinazolinonderivate als parp-hemmer
WO2006013896A1 (ja) 2004-08-04 2006-02-09 Meiji Seika Kaisha, Ltd. キノリン誘導体およびそれを有効成分として含んでなる殺虫剤
KR100686531B1 (ko) 2004-08-31 2007-02-23 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
EP1815247B1 (en) 2004-11-05 2013-02-20 Janssen Pharmaceutica NV Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
JO2855B1 (en) 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JP5112083B2 (ja) 2006-02-03 2013-01-09 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規キノリン誘導体およびこれを有効成分として含有する農園芸用殺菌剤
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
PT2081937E (pt) 2006-10-23 2012-10-15 Sgx Pharmaceuticals Inc Moduladores de proteína-cinase de triazolo-piridazina
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
JP2010528991A (ja) 2007-05-21 2010-08-26 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 複素環式キナーゼ調節因子
CN101143845B (zh) 2007-10-15 2010-08-25 中国药科大学 取代喹啉甲酰胍衍生物、其制备方法及其医药用途
US8227499B2 (en) 2008-01-18 2012-07-24 Allergan, Inc. Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
CA2724293A1 (en) 2008-05-13 2009-11-19 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
WO2010068296A1 (en) 2008-12-11 2010-06-17 Stiefel Laboratories, Inc. Piperazine carboxamidines as antimicrobial agents
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
CN101899011B (zh) 2009-05-26 2013-01-16 北京大学 氨基二硫代甲酸酯类化合物、其制备方法和应用
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
JP2013523192A (ja) 2010-04-15 2013-06-17 クロモセル コーポレーション 苦味を低減または排除する化合物、組成物、および方法
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
EP2678052B1 (en) 2011-02-24 2018-09-26 Emory University Jab1 blocking compositions for ossification and methods related thereto
US8604069B2 (en) 2011-04-28 2013-12-10 Japan Tobacco Inc. Amide compound and medicinal use thereof
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
HK1213248A1 (zh) 2016-06-30
KR20150070347A (ko) 2015-06-24
NZ706775A (en) 2018-10-26
IL237866B (en) 2018-05-31
MX358508B (es) 2018-08-22
EP2909192B1 (en) 2017-05-17
CA2888210A1 (en) 2014-04-24
US20140107094A1 (en) 2014-04-17
SI2909192T1 (sl) 2017-08-31
MY189505A (en) 2022-02-16
AR093017A1 (es) 2015-05-13
TWI606045B (zh) 2017-11-21
PE20150778A1 (es) 2015-05-23
CR20150193A (es) 2015-05-18
NI201500053A (es) 2020-03-18
PH12015500817B1 (en) 2015-06-08
CA2888210C (en) 2021-02-09
ME02794B (me) 2018-01-20
EA201590736A1 (ru) 2015-09-30
LT2909192T (lt) 2017-07-10
AU2013331496A1 (es) 2015-04-09
US9290476B2 (en) 2016-03-22
ES2632269T3 (es) 2017-09-12
WO2014062658A1 (en) 2014-04-24
SG11201502369XA (en) 2015-05-28
ZA201503418B (en) 2017-11-29
MX2015004783A (es) 2015-08-14
WO2014062658A8 (en) 2014-07-10
PT2909192T (pt) 2017-08-04
EA026415B1 (ru) 2017-04-28
JP2015536320A (ja) 2015-12-21
AU2013331496B2 (en) 2017-07-27
HRP20171082T1 (hr) 2017-10-06
CL2015000945A1 (es) 2015-08-28
HUE035335T2 (en) 2018-05-02
PH12015500817A1 (en) 2015-06-08
UY35084A (es) 2014-04-30
CY1119234T1 (el) 2018-02-14
JP6466335B2 (ja) 2019-02-06
RS56283B1 (sr) 2017-12-29
CN105209453A (zh) 2015-12-30
GT201500093A (es) 2017-09-26
PL2909192T3 (pl) 2017-09-29
CN105209453B (zh) 2017-06-20
TW201427969A (zh) 2014-07-16
EP2909192A1 (en) 2015-08-26
DK2909192T3 (en) 2017-08-07
BR112015008308A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
ECSP15015022A (es) Moduladores de quinolinilo unidos a metileno de ror-gamma-t
ECSP15015155A (es) Moduladores de quinolinilo unidos a fenilo de ror–gamma–t
CY1124022T1 (el) Σχημα χορηγησης για νιτροκατεχολες
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
UY36377A (es) Compuestos tiazoles sustituidos como moduladores del receptor nuclear ror t y composiciones farmacéuticas que los contienen
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
AR108344A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORgT
EA201491610A1 (ru) Модуляторы x рецепторов печени
UY33323A (es) Análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
MX2015003899A (es) Modulares de la sintesis de andrógenos.
CL2012002079A1 (es) Compuestos derivados del alquil-6-arilsulfamoil-ciclohexen-carboxilato para suprimir un trastorno periferico inducido por agente anti-cancerigeno.
AR094318A1 (es) Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o enfermedad cognitivo, neurodegenerativo o neuronal
EA201590656A1 (ru) Азаиндолины
BR112016008215A2 (pt) moduladores de quinolinila ligados por alquila de roryt